Preparation method of GluN2B single-domain antibody

By constructing the recombinant GluN2B glutamate binding domain protein S1-GT-S2, a highly selective and high-affinity GluN2B single domain antibody was developed, which solved the problem of off-target effects of existing GluN2B antagonists and achieved specificity for GluN2B subunit Sexual antagonism provides ideas for the development of new antagonists.

CN118894933APending Publication Date: 2024-11-05HEBEI UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310491333.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-05
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing GluN2B antagonists have problems with off-target effects, which leads to their poor effectiveness in clinical applications and lack of novel antagonists with high selectivity and high affinity.

Method used

By constructing the recombinant GluN2B glutamate binding domain protein S1-GT-S2 as an immunogen, a highly selective and highly affinity GluN2B single domain antibody is developed, using its specific binding to the GluN2B glutamate binding domain to interfere with the agonism The binding of the agent glutamate and GluN2B achieves functional antagonism.

Benefits of technology

The development of high-selectivity and high-activity GluN2B antagonists has been achieved, which can distinguish different types of GluN2 subunits, interfere with the binding of agonists with GluN2B, and provides the development idea of ​​a new antagonist that has both high-selectivity and high-activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention discloses a preparation method of a GluN2B single-domain antibody acting on a glutamic acid binding site. The preparation method comprises the following steps: expression and identification of a GluN2B glutamic acid binding structural domain, construction of a phage library of the GluN2B single-domain antibody, enrichment and screening of the GluN2B single-domain antibody, and expression, purification and identification of the GluN2B single-domain antibody. The recombinant GluN2B glutamic acid binding domain protein is used as an antigen to construct the GluN2B single-domain antibody acting on a glutamic acid binding site, and a methodological basis can be provided for developing a high-selectivity single-domain antibody GluN2B antagonist.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of bioengineering technology, and in particular to a method for preparing a GluN2B single domain antibody. Background Art

[0002] Central nervous system diseases are one of the main factors affecting global disability-adjusted life years, and the number of people with such diseases accounts for about one-sixth of the world's population. Central nervous system diseases seriously threaten people's lives and health, and also increase the economic burden of social medical insurance. At present, the treatments for nervous system diseases mainly include chemotherapy, cell therapy, gene therapy, etc., among which GluN2B antagonists have a relatively broad application prospect. Although various types of GluN2B antagonists have been developed, none of the existing antagonists have been used in clinical practice, and the development of new GluN2B antagonists is particularly important.

[0003] In recent years, single-domain antibodies have gradually become a hot topic in the development of new drugs due to their unique structure and characteristics. This paper uses recombinant GluN2B glutamate binding domain protein (S1-GT-S2 protein) as an antigen to construct a GluN2B single-domain antibody that acts on the glutamate binding site, which can provide a basis for the development of highly selective single-domain antibody-type GluN2B antagonists. Summary of the invention

[0004] The purpose of the present invention is to provide a method for preparing a GluN2B single domain antibody, aiming to solve the disadvantage that existing GluN2B antagonists have off-target effects.

[0005] To achieve the above objectives, the present invention provides a method for preparing a GluN2B single domain antibody, comprising the following four steps: expression and identification of the GluN2B glutamate binding domain, construction of a GluN2B single domain antibody phage library, enrichment and screening of the GluN2B single domain antibody, and expression, purification and identification of the GluN2B single domain antibody.

[0006] The present invention innovatively connects two non-continuous sequences S1 and S2 of the GluN2B glutamate binding domain using GT as a linker to construct a recombinant GluN2B glutamate binding domain protein as an immunogen.

[0007] The single-domain antibody constructed by the present invention can produce strong and specific binding with the GluN2B glutamate binding domain. This technology is an effective technical means for developing highly selective and high-affinity GluN2B ligands.

[0008] Since antibodies have the function of distinguishing subtle differences in spatial conformation, the single-domain antibody constructed in the present invention can distinguish different types of GluN2 subunits.

[0009] Since the single-domain antibody constructed by the present invention acts on the glutamate binding site of the GluN2B subunit, it can interfere with the binding of the agonist glutamate and GluN2B, thereby producing a functional antagonistic effect.

[0010] The method used in the present invention helps to provide ideas for developing novel GluN2B antagonists with both high selectivity and high activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 This is the electrophoresis diagram of PCR amplification of S1-GT-S2 gene. The product size is about 1000 bp, which is basically consistent with the expected target gene size.

[0012] Figure 2 As the restriction endonuclease identification map of the recombinant plasmid, the recombinant plasmid was double-digested with Mlu I and Xho I restriction endonucleases to obtain two fragments of approximately 1600 and 4000 bp in size, which were consistent with the expected size in the recombinant plasmid map.

[0013] Figure 3 This is the electrophoresis diagram of S1-GT-S2 protein. The theoretical molecular weight of S1-GT-S2 protein is 34 kDa. The results show that there is an obvious single band between 30-35 kDa, which is consistent with theoretical expectations.

[0014] Figure 4 This is the ELISA identification result of serum antibody titer. After three immunizations of alpacas, the serum titer reached above 1:81000, which met the requirements for constructing an antibody library.

[0015] Figure 5 This is the result of total RNA gel electrophoresis. After immunizing the alpaca three times with S1-GT-S2 protein, peripheral blood was collected to separate white blood cells. After extracting total RNA, electrophoresis was performed. The three bands on the agar gel electrophoresis diagram are: 28S, 18S, and 5S from top to bottom. The electrophoresis results show that the 28S and 18S bands are relatively clear, indicating that the RNA is effectively extracted without obvious degradation. It can be used for reverse transcription synthesis of cDNA to amplify antibody variable region genes.

[0016] Figure 6 This is the result of the second round of PCR amplification of the antibody gene. The second round of PCR amplification used the product of the first round as a template to further amplify the antibody gene and obtained a target gene of about 500 bp, which is consistent with the expected size of the single-domain antibody gene fragment.

[0017] Figure 7 This is the result of positive clone identification. 96 monoclonal colonies were randomly selected for antigen binding ability identification. The experimental group was P and the control group was N. The positive clone strains were those with P exceeding N by 2.1 times. Finally, 44 positive clone strains were obtained.

[0018] Figure 8 This is a diagram of single domain antibody gene PCR amplification. As shown in the figure, the product is consistent with the expected single domain antibody gene size (453bp), indicating that the single domain antibody gene was successfully amplified.

[0019] Fig. 9 This is the electrophoresis diagram of the single domain antibody. The theoretical molecular weight of the S1-GT-S2 single domain antibody is 14 kDa. The electrophoresis results show an obvious band around 14 kDa, indicating that the S1-GT-S2 single domain antibody is expressed normally, and the protein has no impurity bands and is of high purity.

[0020] Fig.10 The results of the single-domain antibody binding activity test with S1-GT-S2 protein show that three single-domain antibodies have strong binding activity with S1-GT-S2 protein. Implementation

[0021] In order to make the purpose, technical solution and advantages of the present invention more clear, the present invention is further described in detail below. The contents described herein are intended to be used to explain the present invention and should not be construed as limiting the present invention.

[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by technicians in the technical field to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.

[0023] In order to further understand the present invention, the present invention is further described in detail below in conjunction with the best embodiment, comprising the following steps:

[0024] Construction of the target gene: The amino acid sequences S1 and S2 of the glutamate binding domain of the GluN2B subunit were connected through GT (glycine and threonine) to form the target gene S1-GT-S2 sequence, and the target gene sequence was handed over to a biological company for optimization and synthesis.

[0025] Amplification of target gene: Design primers, use PCR instrument to amplify target gene S1-GT-S2, and use PCR product recovery kit to recover the product.

[0026] Double restriction enzyme digestion of vector plasmid: pcDNA3.1 vector was double-digested with Mlu I and Xho I restriction endonucleases.

[0027] Recombinant plasmid construction: The vector recovered from gel excision was connected to the target fragment using T4 DNA ligase and placed in a water bath at 50°C for 20 min.

[0028] Transformation of ligation product: Transform the ligation system pcDNA3.1-His-S1-GT-S2 into DH5α competent cells.

[0029] Extraction of recombinant plasmid: Extract the plasmid from the positive cloned bacterial solution using a plasmid extraction kit.

[0030] Double enzyme digestion identification of recombinant plasmid: The recombinant plasmid was double digested with Mlu I and Xho I restriction endonucleases.

[0031] Expression and purification of recombinant protein: The pcDNA3.1-His-S1-GT-S2 plasmid was transfected into HEK293 cells for expression. The protein was secreted and expressed when the HEK293 cells were cultured to the seventh day.

[0032] Identification of recombinant protein: SDS-PAGE gel electrophoresis was used to detect the purity and size of S1-GT-S2 protein.

[0033] Immunization of alpacas: Before immunizing alpacas, 5 mL of peripheral blood was collected, and serum was extracted as negative serum, which was stored at -20°C for later use. Multiple injections were made into the subcutaneous part of the neck of alpacas using S1-GT-S2 protein (mixed in a volume ratio of 1:1 between protein and adjuvant, and vibrated vigorously to fully emulsify). The immunization dose was 1 mg, and the injection interval was 14 days. Before injection, be careful to avoid the previous immunization site. 5 mL of peripheral blood was drawn after the second and third immunizations, and centrifuged at 500´g for 15 min at 4°C. The upper serum was extracted for titer detection.

[0034] Serum titer detection: The sera before immunization, the second immunization, and the third immunization were separated and the sera were subjected to ELISA titer detection. The S1-GT-S2 protein was used as the antigen, the sera before and after immunization were used as the primary antibody, and Goat Anti-Alpaca IgG (HRP) was used as the secondary antibody.

[0035] Isolation of alpaca leukocytes: 100 mL of whole blood was collected from the jugular vein of the alpaca, and leukocytes were extracted after adding red blood cell lysis buffer in batches.

[0036] Extraction of total RNA: RNA was extracted using a Trizol kit, including phase separation, isopropanol RNA precipitation, washing RNA precipitation, dissolving RNA precipitation, and agarose electrophoresis to verify the integrity of RNA.

[0037] cDNA synthesis: Synthesize cDNA according to the requirements of the reverse transcription kit. The RNA template input amount is 10 µg and the total reverse transcription volume is 50 µL.

[0038] Amplification of VHH gene: VHH gene was amplified by two rounds of PCR reactions using cDNA and the first round PCR product as templates respectively.

[0039] The VHH gene was connected to the pComb3X vector: the recovered fragment and the pComb3X vector were digested with Sfi I restriction endonuclease, and the recovered pComb3X vector and the digested fragment were connected with a ligase at 4°C overnight.

[0040] Electroporation of competent XL1-Blue cells: Use an electroporator to obtain competent XL1-Blue cells.

[0041] Preliminary identification of the antibody library: Take 100 mL of bacterial solution from the antibody bacterial library and dilute it in a 10-fold dilution method using 2YT medium. Then, apply 100 mL of the diluted bacterial solution evenly on the 2YT-ATG semi-solid medium containing ampicillin and tetracycline. Place the plate upside down in a 37°C incubator overnight for 17 hours. Count the monoclonal colonies the next day and calculate the number of transformants, i.e., the storage capacity of the antibody library.

[0042] Phage library expression amplification: The phage library solution was continued to be shaken and cultured, and VCSM13 helper phage was added to amplify the expression of the phage library.

[0043] Enrichment and screening of GluN2B single domain antibodies: GluN2B single domain antibodies were enriched and screened using S1-GT-S2 proteins, including antigen coating, blocking, incubation of phages, elution, infection, rescue, concentration and purification of phage particles, with a total of 5 rounds of enrichment and screening.

[0044] Identification of positive clones: The amplified library of the fifth round was used for ELISA detection. 96 monoclonal colonies were selected from the library, and the supernatant after phage expression was used for ELISA to detect phage enrichment, including steps such as coating antigen, blocking, adding phage, incubating secondary antibodies, and color development. The absorbance was detected at 450 nm, and the experimental group was judged to be positive if it exceeded the negative control group by more than 2.1 times.

[0045] Single domain antibody gene amplification: Use a PCR instrument to amplify the single domain antibody sequence.

[0046] Vector plasmid digestion: pcDNA3.1 vector was double digested with Bam HI / Xho I restriction endonucleases.

[0047] Recombinant plasmid construction: The vector recovered from gel excision is connected with the target fragment through recombinase.

[0048] Transformation of ligation products: The ligation products were transformed into DH5α competent cells.

[0049] Extraction of recombinant plasmid: Use a plasmid extraction kit to extract the plasmid.

[0050] Transfection of HEK293 cells: PEI transfection reagent was used for transfection of HEK293 cells.

[0051] Expression and purification of single domain antibodies: HEK293 cells were cultured for protein secretion expression until the seventh day. The cell supernatant was centrifuged at 4°C, 3000 rpm, 50 min, and filtered through a 0.22 mm filter membrane. The samples were collected for protein purification.

[0052] Identification of recombinant single domain antibodies: Use SDS-PAGE gel to detect the purity of the target protein.

[0053] Affinity activity detection: Using S1-GT-S2 protein as the antigen, the affinity activity of the single domain antibody was detected by ELISA method, including protein coating, blocking, sample addition, incubation with secondary antibody, TMB color development and other steps.

Claims

1. A method for preparing a GluN2B monoclonal antibody, It is characterized in that The following steps are involved: Step S1: constructing a pcDNA3.1-His-S1-GT-S2 plasmid carrying the GluN2B glutamate binding domain sequence gene, introducing the recombinant plasmid into mammalian HEK293 cells to express the target protein, and purifying the S1-GT-S2 protein by nickel affinity chromatography; Step S2: Immunize alpacas with S1-GT-S2 protein, extract RNA, amplify the GluN2B single domain antibody gene sequence by nested PCR after reverse transcription, connect the gene to pComb3X vector and transform it into Escherichia coli XL1-Blue to construct a GluN2B single domain antibody phage display library; Step S3: Enrich and screen the phage library using the S1-GT-S2 protein, and identify positive strains by enzyme-linked immunosorbent assay (ELISA); Step S4: Connect the positive cloned gene to the eukaryotic expression vector pcDNA3.1, transfect into HEK293 cells for expression and purification of the single domain antibody, and perform affinity activity detection on the obtained GluN2B-specific single domain antibody.

2. A method for preparing a GluN2B monoclonal antibody according to claim 1, Features: In step S1, GT is used as a linker to connect the two non-continuous sequences S1 and S2 of the GluN2B glutamate binding domain, and S1-GT-S2 is used as the target gene to construct a recombinant GluN2B glutamate binding domain protein, namely, S1-GT-S2 protein.

3. The method for preparing a GluN2B monoclonal antibody according to claim 1, Features: In step S1, the S1-GT-S2 protein is His-tagged and can be purified using a nickel affinity chromatography column.

4. The method for preparing a GluN2B monoclonal antibody according to claim 1, Features: In step S2, nested PCR was used to amplify the VHH gene, thereby improving the specificity of PCR amplification.

5. The method for preparing a GluN2B monoclonal antibody according to claim 1, Features: In step S3, the phage library is enriched and screened using VCSM13 helper phage, which is a relatively common type of phage and has the advantages of producing high titers of recombinant phagemids and strong specificity for target proteins.